−3.44EUR
−147.74 MEUR
45.87 M
About ABIVAX SA EO -,01
Sector
CEO
Marc M. P. de Garidel
Headquarters
Paris
Website
Employees (FY)
61
Founded
2013
ISIN
FR0012333284
FIGI
BBG00GNG2LD0
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ABIVAX SA EO -,01 stocks are traded under the ticker 2X1.
ABIVAX SA EO -,01 is going to release the next earnings report on Sep 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for ABIVAX SA EO -,01 has a max estimate of 65.00 EUR and a min estimate of 14.94 EUR.
Yes, you can track ABIVAX SA EO -,01 financials in yearly and quarterly reports right on TradingView.
Like other stocks, 2X1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIVAX SA EO -,01 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 61.00 employees. See our rating of the largest employees — is ABIVAX SA EO -,01 on this list?